Published in Hepatitis Weekly, December 26th, 2005
"To gain understanding of inter-individual differences of treatment response in HCV genotype 1 (HCV-G1) patients, we investigated simultaneously the early HCV kinetics and virus-specific T-cell reactivity," wrote K.H. Tang and colleagues, University College London.
"Thirty treatment-naive HCV-G1 patients received peginterferon-alfa2a (180 mcg/week) plus ribavirin (10,001,200 mg/day), with blood samples collected prospectively at protocol time-points. HCV RNA was quantitated with a TaqMan assay with mathematical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.